To NASDAQ OMX Copenhagen A/S
Investor News No. 04-12 / Copenhagen, August 23,
2012
Copenhagen, Denmark - August 23, 2012 - Topotarget A/S (NASDAQ OMX: TOPO) announces that a teleconference will be held on August 29, 2012 at 1:00 pm CET. CEO Francois Martelet, CMDO Axel Mescheder, and CFO Anders Vadsholt will present the interim report for Q2 2012 and answer questions. The teleconference will be conducted in English. A presentation will be available on Topotarget's website, www.topotarget.com, before the start of the conference call.
To participate in the conference call please dial:
- From Denmark: 32 72 76 25
- Outside Denmark: +44 (0) 1452 555566
A replay of the conference call will be available approximately four hours after the conference call and until September 11, 2012 at: +45 70 14 21 68 or +44 (0) 145 255 0000, pass code: #22283673. Areplay will also be available on Topotarget's website www.topotarget.com.
Topotarget A/S
For further information, please contact:
Anders Vadsholt, CFO: Direct: +45 39 17 83
45
Background information
About Topotarget A/S
Topotarget (NASDAQ-OMX: TOPO) is an international
biopharmaceutical company headquartered in Copenhagen,
Denmark, dedicated to clinical development and registration
of oncology products. Topotarget focuses, in collaboration
with Spectrum Pharmaceuticals, Inc., on the development in
pivotal studies of its lead drug candidate, belinostat,
which has shown positive results as a monotherapy treating
hematological malignancies and positive results in solid
tumors. Belinostat may be used in combination with full
doses of chemotherapy, and is in a pivotal trial within
PTCL (peripheral T-cell lymphoma). For more information,
please visit www.topotarget.com.
Topotarget A/S Safe Harbor Statement
This announcement may contain forward-looking
statements, including statements about our expectations of
the progression of our pre-clinical and clinical pipeline
including the timing for commencement and completion of
clinical trials and with respect to cash burn guidance.
Such statements are based on management's current
expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ
materially from those described in the forward-looking
statements. Topotarget A/S cautions investors that there
can be no assurance that actual results or business
conditions will not differ materially from those projected
or suggested in such forward-looking statements as a result
of various factors, including, but not limited to, the
following: The risk that any one or more of the drug
development programs of Topotarget A/S will not proceed as
planned for technical, scientific, or commercial reasons or
due to patient enrollment issues or based on new
information from non-clinical or clinical studies or from
other sources; the success of competing products and
technologies; technological uncertainty and product
development risks; uncertainty of additional funding;
Topotarget A/S' history of incurring losses and the
uncertainty of achieving profitability; Topotarget A/S'
stage of development as a biopharmaceutical company;
government regulation; patent infringement claims against
Topotarget A/S' products, processes, and technologies;
the ability to protect Topotarget A/S' patents and
proprietary rights; uncertainties relating to
commercialization rights; and product liability exposure.
We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, unless required
by law.
distributed by |